The original success of Sildenafil undeniably reshaped the medication landscape, but here placing funds in companies strongly reliant on off-patent versions presents a complex picture. Although early earnings were significant, the end of patents and the emergence of discounted alternatives have diminished the customer base. Therefore, a thorough an